Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Clin Lipidol. 2011 Aug 1;6(4):371–387. doi: 10.2217/clp.11.37

Figure 4. Variable changes in lipid subfractions among subjects treated with pioglitazone and rosiglitazone despite equivalent glycemic control in the GLAI Study.

Figure 4

Despite no significant differences in glycemic control, considerable variability is observed in the lipid subfractions of patients receiving PIO versus ROS in the GLAI Study [58,59].

HgbA1c: Hemoglobin A1c; PIO: Pioglitazone; ROS: Rosiglitazone.